Quantcast
Last updated on April 18, 2014 at 14:49 EDT

Latest Drug delivery Stories

2013-06-05 08:29:18

DUBLIN, June 5, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/k8vlr3/transdermal_drug) has announced the addition of the "Transdermal Drug Patches to 2018 Products, Indications, Markets and Forecasts" [http://www.researchandmarkets.com/research/k8vlr3/transdermal_drug ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Transdermal drug patches offer the advantages of ease of use,...

2013-06-03 08:28:19

BD Neopak(TM) Prefillable Syringe System Commercially Launched Worldwide FRANKLIN LAKES, N.J., June 3, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the launch of BD Neopak(TM), a new glass prefillable syringe system specifically engineered for the administration of biopharmaceutical injectable drugs. This new product is designed to address industry challenges in developing,...

2013-05-31 08:24:38

CANTON, Mass., May 31, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Tuesday, June 4, 2013 at 3:00pm EDT at the Jefferies 2013 Global Health Care Conference. The conference will be held at the Grand Hyatt New York in New York City. The Company's lead development program is Oxycodone DETERx(®), an abuse-deterrent,...

2013-05-28 23:03:46

In response to client requests, Integral BioSystems is developing and will be licensing Integral´s novel platform ophthalmic formulation technologies for use in treatment of disease in both the front and the back of the eye. Bedford, MA (PRWEB) May 28, 2013 Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D., is developing and will offer for license its novel, platform front-of-the-eye and back-of-the-eye ophthalmic therapeutic...

2013-05-24 04:20:16

LONDON, May 24, 2013 /PRNewswire/ -- The potential of the pulmonary route as a non-invasive administration for systemic delivery of therapeutic agents has been receiving undeniable attention with the recent advances of the inhalation drug delivery showing significant promise. The crucial formulation considerations for orally inhaled products together with those of a delivery device play a major role in the efficiency of pulmonary delivery, and great strides have been made in the...

2013-05-21 08:30:06

ALBANY, New York, May 21, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Biochip Products and Services Market (Microarrays, Reagents, Drug Discovery, Life Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market was valued at USD 2.4 billion in 2011 and is expected to grow at a CAGR of 10.1% from 2012 to 2018, to reach an...

2013-05-17 08:24:07

FARMINGTON, Conn., May 17, 2013 /PRNewswire-iReach/ -- The escalation of new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Alternate delivery technologies are on the rise as a number of factors are converging to create both risk and opportunity for pharmaceutical makers and their delivery device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward...

2013-05-17 08:23:06

CANTON, Mass., May 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Monday, May 20, 2013 at 1:30pm EDT at the UBS Global Health Care Conference. The conference will be held at the Sheraton New York Hotel in New York City. The Company's lead development program is Oxycodone DETERx(®), an abuse-deterrent, extended-release...

2013-05-15 12:35:00

FARMINGTON, Conn., May 15, 2013 /PRNewswire-iReach/ -- World Pharma Congress is celebrating 12 years of preclinical research with its annual event covering the latest in drug targets, high-throughput screening, lead optimization, ADME and drug safety. Years of effectively covering the latest preclinical strategies and technologies that drive better predictions has culminated in priming this year's event to move further downstream into early formulations and drug delivery. (Photo:...

2013-05-14 08:32:07

Aegis' Intravail® formulation of sumatriptan achieves therapeutic drug levels in approximately 2 to 3 minutes SAN DIEGO, May 14, 2013 /PRNewswire-iReach/ -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,440,631, its second patent providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and...